Top Medical Stocks To Add to Your Watchlist – July 17th

UnitedHealth Group, Abbott Laboratories, Eli Lilly and Company, Elevance Health, Johnson & Johnson, Pfizer, and Carmell are the seven Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks are shares of publicly traded companies involved in the healthcare sector, including pharmaceuticals, biotechnology, medical devices, diagnostics and healthcare services. By purchasing these equities, investors gain exposure to the industry’s growth drivers—such as drug approvals, clinical research breakthroughs and demographic trends that increase demand for medical care. Their performance can be shaped by regulatory decisions, patent expirations, reimbursement policies and shifting healthcare needs. These companies had the highest dollar trading volume of any Medical stocks within the last several days.

UnitedHealth Group (UNH)

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

NYSE:UNH traded down $3.76 during mid-day trading on Thursday, reaching $288.73. The company’s stock had a trading volume of 8,927,810 shares, compared to its average volume of 7,759,405. UnitedHealth Group has a 12-month low of $248.88 and a 12-month high of $630.73. The firm’s fifty day moving average price is $308.39 and its two-hundred day moving average price is $436.45. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 0.71. The stock has a market cap of $261.92 billion, a P/E ratio of 12.09, a PEG ratio of 1.40 and a beta of 0.45.

Abbott Laboratories (ABT)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Shares of NYSE ABT traded down $11.05 during midday trading on Thursday, hitting $120.69. 15,948,352 shares of the company’s stock traded hands, compared to its average volume of 6,206,614. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $141.23. The stock has a market capitalization of $209.98 billion, a price-to-earnings ratio of 15.65, a price-to-earnings-growth ratio of 2.50 and a beta of 0.73. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.27 and a current ratio of 1.78. The firm has a fifty day moving average of $133.43 and a 200 day moving average of $129.32.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of NYSE LLY traded down $23.88 during midday trading on Thursday, hitting $765.92. 1,883,730 shares of the company’s stock traded hands, compared to its average volume of 3,675,691. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The stock has a market capitalization of $725.89 billion, a price-to-earnings ratio of 62.34, a price-to-earnings-growth ratio of 1.12 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The firm has a fifty day moving average of $766.12 and a 200 day moving average of $799.91.

Elevance Health (ELV)

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

Shares of NYSE ELV traded down $39.12 during midday trading on Thursday, hitting $305.43. 4,027,464 shares of the company’s stock traded hands, compared to its average volume of 1,647,193. Elevance Health has a 1 year low of $297.56 and a 1 year high of $567.26. The stock has a market capitalization of $69.00 billion, a price-to-earnings ratio of 11.94, a price-to-earnings-growth ratio of 0.85 and a beta of 0.60. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.43 and a current ratio of 1.43. The firm has a fifty day moving average of $376.31 and a 200 day moving average of $396.73.

Johnson & Johnson (JNJ)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Shares of NYSE JNJ traded down $1.74 during midday trading on Thursday, hitting $163.04. 5,012,450 shares of the company’s stock traded hands, compared to its average volume of 8,137,822. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The stock has a market capitalization of $392.29 billion, a price-to-earnings ratio of 18.14, a price-to-earnings-growth ratio of 2.12 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The firm has a fifty day moving average of $153.95 and a 200 day moving average of $154.71.

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Pfizer stock traded down $0.09 during midday trading on Thursday, hitting $24.53. The stock had a trading volume of 27,830,455 shares, compared to its average volume of 41,894,555. The firm’s fifty day moving average is $23.99 and its two-hundred day moving average is $24.77. The company has a market capitalization of $139.43 billion, a PE ratio of 17.77, a P/E/G ratio of 0.90 and a beta of 0.58. Pfizer has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Carmell (CTCX)

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products.

Carmell stock traded up $3.06 during midday trading on Thursday, hitting $5.70. The stock had a trading volume of 103,613,558 shares, compared to its average volume of 4,503,394. The firm’s fifty day moving average is $2.52 and its two-hundred day moving average is $1.05. Carmell has a 52-week low of $0.17 and a 52-week high of $1.59.